An appendix describing study considerations and instructions based on the COVID-19 global health crisis was added. • Exclusion criterion #14 was modified to clarify that subjects were to be excluded if they had received an investigational drug within 30 days or 5 half-lives before study entry (Visit 1). • Exclusion criterion #22a was modified to remove the provision of a >3 × ULN limit of total bilirubin with Gilbert’s syndrome such that any subject with >1.5 × ULN total bilirubin was excluded, and exclusion criterion #22b was modified to specify upper limits for transaminases if elevated due to the course of the subject's malignancy. • For subjects who were discontinued by the investigator due to safety concerns, an additional visit was added after 3 months for laboratory assessments. • Prohibited therapies were modified to indicate that study treatment was to be postponed in case any unforeseeable vaccinations were necessary during the study, and text describing the permitted palliative radiotherapy was clarified. • Changes were made to indicate that the sponsor would provide access to further treatment with atezolizumab after the end of the study (if clinically indicated). • Text was added to indicate that results of safety laboratory tests and pregnancy tests were to be reviewed before study treatment was administered. • National Cancer Institute (NCI) CTCAE (Versions 4.0 and 5.0) grading details for a range of potential AEs associated with the use of atezolizumab were included in an appendix. Changes were made to reflect revisions in an addendum to the current atezolizumab IB and SPC, including changes regarding management of atezolizumab-specific AEs. • Exclusion criteria were modified to state that active, known, or suspected autoimmune disease would lead to exclusion and a new section listing exclusionary autoimmune diseases was added. • Subgroup analyses by PD-L1 status and tumour type were added to the statistical methods section of the protocol

This global protocol amendment was implemented for several reasons. Some of the changes made were as follows: • Information on a newly identified risk for treatment with atezolizumab was added, after the manufacturer confirmed a risk of severe cutaneous adverse reactions. • The text describing the final study visits for subjects completing the study and for those terminating early and the text describing the handling of missing/delayed treatments were clarified. • The Schedule of Events was modified to show the quarterly telephone calls during follow-up and the pregnancy tests that are conducted at home by subjects for the first 6 months of follow-up. • Collection of laboratory blood samples the day before administration of study treatment (including Visit 1) was added. • Instructions for the collection, processing, and shipping of blood samples for evaluation of peripheral T-cell response were added. • The acceptability of local imaging assessment for subject management by the investigator was clarified. • The sample size was modified in case of a larger than expected drop-out rate. • An appendix describing the process for conducting remote source data verification was added. • Circumstances allowing rescreening of screen-failed subjects were updated. • The option of subject consent for remote screening was added in light of the COVID-19 pandemic and to reduce unnecessary travel. • Text suggesting that archived samples could only be used from subjects who had received prior anticancer therapy was removed. • Reporting of disease progression as an AE was clarified. • Different changes were made to the eligibility criteria.

This global protocol amendment was implemented for several reasons. The changes made were as follows: • The sponsor’s name was updated, after VACCIBODY AS changed their name to Nykode Therapeutics ASA. • Information on the management of atezolizumab-specific AEs was updated, as described in the most recent IB (Version 18, July 2021; Addendum 1, August 2021). • The ongoing use of atezolizumab in patients who completed the 48 weeks of planned study treatment was clarified, including clarification regarding AE reporting during this time.